NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

And more pharma news updates from Pharmalittle.

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

pharmaphorum’s Managing Editor, Rebecca Aris, speaks with Gary Hendler of Eisai on Eisai’s current pipeline, what disease areas it will be focussing on and how its latest epilepsy drug ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The decision was closely watched by patient advocates and scientists alike because Eisai and Biogen's drug, sold under the brand name Leqembi, is the first beta amyloid-targeting medication to ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...

SAN FRANCISCO, Nov 30 (Reuters) - Japan's Eisai Co (4523.T), opens new tab plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed ...

Two potential treatment-related deaths have dimmed the initial glow surrounding Eisai and Biogen’s next Alzheimer’s disease therapy lecanemab. But the Japanese company believes it has more ...

Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug. Sign up here. The drug, to be sold under the brand Leqembi, belongs to a class of treatments ...